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A Case of Portal Vein Thrombosis by Protein C and S Deficiency 
Completely Recanalized by Anticoagulation Therapy
Bo Kyoung Choi, Soo Hyun Yang*, Kang Hum Suh, Jin Ah Hwang, Moon Hyung Lee, Won Keun 
Si and Ji Ho Kim
Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea
Portal vein thrombosis (PVT) is a rare form of venous thrombosis that affects the hepatic 
portal vein flow, which can lead to portal hypertension. Treatment of PVT includes anti-
coagulants, thrombolysis, insertion of shunts, bypass surgery, and liver transplanta-
tion. Single anticoagulation therapy is not regarded as a curative treatment but can 
be associated with a reduction in new thrombotic episodes. We experienced a case of 
acute total occlusion of PVT provoked by protein C and S deficiency syndrome. PVT 
was completely recanalized with oral anticoagulant therapy following low molecular 
weight heparin therapy.
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INTRODUCTION
The first report of portal vein thrombosis (PVT) was 
made in 1868. That was a type of phlebothrombosis compli-
cated with portal hypertension and a reduction of the blood 
flow to the liver. Owing to various symptoms in PVT, it is 
difficult to make an accurate diagnosis clinically.
1 PVT 
causes portal hypertension and varix, and if severe, can 
cause variceal hemorrhage and ischemic bowel disease.
1
The pathogenesis of PVT has not been identified clearly, 
but recent studies report that it is related to systemic caus-
es such as protein C, protein S, and antithrombin III defi-
ciency disorder.
2 However, there are very few studies of op-
timal treatment owing to the low incidence rate (less than 
0.004%).
3
In Korea, there are several reports of acute PVT caused 
by oral contraceptives and pancreatitis, but few cases of 
PVT caused by a deficiency of anticoagulant factors and re-
perfused with anticoagulation therapy.
4 We report a case 
of PVT caused by protein C and S deficiency that ended in 
successful reperfusion with anticoagulation therapy.
CASE REPORT
A 66-year-old man was admitted via the emergency de-
partment because of systemic myalgia and anorexia last-
ing for 2 weeks. He complained of high fever, nausea, and 
vomiting, and the results of liver function tests were 
abnormal.
He had taken antihypertensive medication for 5 years 
and clopidogrel for 4 years owing to a history of transient 
ischemic attack. He had no history of diabetes mellitus or 
liver diseases. He had undergone subtotal gastrectomy for 
early gastric cancer 2 years ago. On admission, his vital 
signs were as follows: blood pressure, 130/70 mmHg; rest-
ing heart rate, 70 beats per minute; respiratory rate, 20 
breaths per minute; and body temperature, 37
oC. His con-
sciousness was clear but his conjunctivae were pale. His 
breath sounds were clear and his heart sounds were regu-
lar with no murmur. He did not complain of tenderness or 
rebound tenderness of the abdomen, and there were no 
signs of hepatomegaly or splenomegaly. The neurologic ex-
amination revealed no abnormal signs. 
The laboratory findings were as follows: white blood cell 
count, 12,080/mm
3 (normal: 4,000-10,000/mm
3); hemoglo-
bin, 10.5 g/dl (13.0-17.0 g/dl); hematocrit, 31.3% (39-52%); 
platelet count, 351,000/mm
3 (150,000-40,000/mm
3); serum 
aspartate aminotransferase (AST), 42 IU/L (0-37 IU/L); se-
rum alanine aminotransferase (ALT), 137 (0-41 IU/L); se-
rum alkaline phosphatase (ALP), 442 IU/L (39-117 IU/L); 
gamma(γ)-glutamyl transferase (γ-GT), 255 IU/L (11-50 
IU/L); serum total bilirubin, 0.9 mg/dl (0.2-1.3 mg/dl); total 186
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FIG. 1. Abdominal CT scan. (A) Ill-de-
fined, flower-like, low attenuations can
be found in the posterior segment of the
liver (microabscess). (B) Massive intra-
hepatic portal vein thrombus and main 
portal vein thrombus can be found.
FIG. 2. Liver Doppler ultrasound. (A) 
The image shows the thrombus in the
intrahepatic portal vein and the widen-
ing of the portal vein diameter. (B) 
There is echogenic material and flow in
the right portal vein lumen and multi-
ple collateral vessels are not shown on 
the porta hepatis. (C) There is no echo-
genic material in the right portal vein
lumen and the flow can be observed. (D) 
The flow and Doppler wave are noted in 
the umbilical portion of the left portal
vein.
protein, 7.3 g/dl (6.7-8.3 g/dl); albumin, 3.0 g/dl (3.5- 5.2 
g/dl); and prothrombin time international normalized ra-
tio (PT INR), 1.21 (0.85-1.15). HBsAg, anti-HBs, and an-
ti-HCV were negative. 
Abdominal CT scan showed complete occlusion of the in-
trahepatic portal vein by portal vein thrombi and small 
hepatic abscess around the occluded vessels (Fig. 1). Abdo-
minal Doppler ultrasound, esophagogastroduodenoscopy, 
and coagulation factor analysis were performed to identify 
the cause of the PVT. The abdominal Doppler ultrasound 
showed complete portal vein occlusion but could not identi-
fy the surrounding microvessels, which implied a low prob-
ability of malignancy (Fig. 2A). Esophagogastroduodeno-
scopy showed no esophageal or gastric varices. Coagulant 
factor VIII and protein C factor were 261% (normal: 60-140%) 
and 41% (normal: 60-140%), respectively. Protein S factor 
showed a decrease of 14% (normal: 60- 140%). Thus, the pa-
tient was diagnosed with PVT caused by a deficiency of pro-
tein C and S.
Administration of warfarin (at a dose of 5 mg twice daily) 
and subcutaneous injection of low molecular weight hep-
arin (enoxaparin, 1 mg/kg, twice daily) was promptly star-
ted. At the time of discharge, the maintenance dose of war-
farin was 2.5 mg per day (target INR: 2-2.5). The abdominal 
Doppler ultrasound, performed just before discharge, re-
vealed that the portal vein was still completely occluded by 
thrombi but decreased in diameter. The results of the labo-
ratory tests conducted on an outpatient basis were as fol-
lows: INR, 1.90; protein C, 41%; protein S, 14%; AST, 61 
IU/L; ALT, 54 IU/L; ALP, 56 IU/L; and rGT, 215 IU/L. Ab-
dominal Doppler ultrasound showed blood flow in the PVT 
(Fig. 2B). The results of the blood tests conducted 6 months 
later were as follows: serum INR, 1.71; AST, 57 IU/L; ALT, 
46 IU/L; ALP, 113 IU/L; and γGT, 121 IU/L. On the abdomi-
nal Doppler ultrasound performed at that time, the portal 
vein thrombi had disappeared and a smooth bloodstream 
was observed in the portal vein (Fig. 2C, D).187
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FIG. 3. Abdominal CT scan 6 months after anticoagulation thera-
py. The portal vein thrombosis has disappeared completely.
DISCUSSION
PVT interrupts blood flow to the liver and causes portal 
hypertension.
3 Phlebothrombosis is caused by local, genet-
ic, or acquired thrombophilic factors.
5 Local factors include 
local inflammatory lesions such as neonatal funiculitis, di-
verticulitis, appendicitis, pancreatitis, duodenal ulcer-
ation, tuberculous lymphadenitis, portal vein injury by 
surgical operations, thrombokinesis, pressure mass effect 
by an abdominal neoplasm, and portal hypertension by liv-
er cirrhosis.
5 Denninger et al. reported that 6% to 11% of 
PVT is attributed to liver cirrhosis, and 35% is related to 
hepatocellular carcinoma.
3 Webb et al. reported that 40% 
of PVT is caused by intraperitoneal or systemic septicemia. 
In other reports, 7% of PVT was reported to be caused by 
chronic pancreatitis.
6 Primary myeloproliferative dis-
order, antiphospholipid antibody syndrome, paroxysmal 
nocturnal hemoglobinuria, oral contraceptives, pregnancy, 
childbirth, malignant tumor, and hypercysteinemia are re-
ported as acquired thrombophilic factors.
5 Genetic throm-
bophilic factors can be divided into the frequent type, such 
as factor V Leiden mutation and mutation IIG20210, in 
which PVT is rarely associated, and the rare type, such as 
protein C, S, and antithrombin III, in which PVT is more 
likely to occur.
5
Clinically, PVT is classified as acute or chronic. However, 
it is difficult to identify when the symptoms begin and even 
the temporal criteria about chronicity have not yet been 
established.
7 Malkowski et al. classified PVT as acute or 
chronic according to symptom onset time before admission 
(60 days).
7 Acute PVT typically provokes stomachache, 
nausea, emesis, and fever. The symptoms can be more severe 
if mesenteric infarction provokes infarction of the bowel or 
liver. Nonspecific symptoms such as diarrhea, anorexia, 
weight loss, and abdominal distention may develop.
8 The 
symptoms of chronic PVT are similar to the acute ones, but 
such symptoms may be related to portal hypertension and 
splenomegaly.
9 Splenomegaly, anemia, leukopenia, throm-
bocytopenia, and variceal bleeding can be provoked.
9
Our case did not develop portal hypertension-related 
complications but showed a fever, stomachache, nausea, 
and emesis, and these symptoms are compatible with PVT. 
Duplex, Doppler ultrasound, and abdominal CT scan can 
be used to make a accurate diagnosis of PVT in the early 
stage, and abdominal MRI can be another diagnostic tool.
10 
In particular, abdominal MRI is known to be more useful 
than Doppler ultrasound in identifying venous collateral 
development and cavernoma.
10 In patients with PVT, local 
factors such as liver cirrhosis and pancreatitis should be 
suspected. If no local factor can be identified, it is necessary 
to investigate genetic or acquired thrombophilic factors.
8
In our case, it was possible to infer that PVT was secon-
dary to a liver abscess of the right lobe. However, it was 
more likely that the abscess was secondary to PVT for the 
following reasons. First, although massive thrombi ob-
structed the main and left portal vein, the abscess was re-
stricted to the right lobe only. Second, it took more than 1 
year after abscess resolution for the cholestatic features on 
the liver function tests to be normalized. Third, antibiotic 
therapy of only 3 weeks brought about a significant in-
crease in main portal vein flow. 
Regarding the treatment of PVT, long-term anticoagu-
lant therapy and invasive methods such as surgical throm-
bectomy, local thrombolytic therapy, thrombolytic agent- 
based selective portography, and intrahepatic stent inser-
tion via the jugular vein can be applied.
9 In many cases, 
chronic PVT is accompanied by gastroesophageal varix, 
which can result in variceal bleeding during anticoagulation 
therapy.
8 In the case of acute PVT, however, early anticoa-
gulant therapy can prevent the spread of thrombi and pro-
mote blood reperfusion.
9 Sheen et al. applied anticoagulant 
therapy to 9 acute PVT patients with a target INR of 2 to 
4 for 3 months. They reported that reperfusion was ach-
ieved in 78%.
1 However, there are no clear guidelines on the 
choice of anticoagulant drugs, the period of administration, 
and even the need for anticoagulant therapy.
7 In our case, 
we successfully treated our acute PVT patient with a 
2-week subcutaneous injection of low molecular weight 
heparin and oral anticoagulant therapy. 
In conclusion, our case shows that PVT can be provoked 
by protein C and S deficiency and that the PVT can be recan-
alized by short-term low molecular heparin plus oral war-
farin therapy. Further study is needed to investigate the 
target INR, the period of administration, and the dosage 
and duration for relapse prevention in treatment with oral 
anticoagulants.
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